Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Teaching NeuroImages: Acute necrotizing encephalopathy of childhood: Neuroimaging findings.

Biswas A, Varman M, Gunturi A, Yoganathan S, Gibikote S.

Neurology. 2018 Jan 9;90(2):e177-e178. doi: 10.1212/WNL.0000000000004800. No abstract available.

PMID:
29311376
2.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

3.

Nivolumab for the treatment of cancer.

Gunturi A, McDermott DF.

Expert Opin Investig Drugs. 2015 Feb;24(2):253-60. doi: 10.1517/13543784.2015.991819. Epub 2014 Dec 12. Review.

PMID:
25494679
4.

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ.

Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15.

5.

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.

Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ.

Cancer. 2014 Jun 1;120(11):1695-701. doi: 10.1002/cncr.28620. Epub 2014 Feb 27.

6.

Potential of new therapies like anti-PD1 in kidney cancer.

Gunturi A, McDermott DF.

Curr Treat Options Oncol. 2014 Mar;15(1):137-46. doi: 10.1007/s11864-013-0268-y. Review.

PMID:
24504486
7.

The role of TCR stimulation and TGF-beta in controlling the expression of CD94/NKG2A receptors on CD8 T cells.

Gunturi A, Berg RE, Crossley E, Murray S, Forman J.

Eur J Immunol. 2005 Mar;35(3):766-75.

8.

The role of CD94/NKG2 in innate and adaptive immunity.

Gunturi A, Berg RE, Forman J.

Immunol Res. 2004;30(1):29-34. Review.

PMID:
15258309
9.

Preferential survival of CD8 T and NK cells expressing high levels of CD94.

Gunturi A, Berg RE, Forman J.

J Immunol. 2003 Feb 15;170(4):1737-45.

10.

Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development.

Sivakumar PV, Gunturi A, Salcedo M, Schatzle JD, Lai WC, Kurepa Z, Pitcher L, Seaman MS, Lemonnier FA, Bennett M, Forman J, Kumar V.

J Immunol. 1999 Jun 15;162(12):6976-80.

Supplemental Content

Loading ...
Support Center